The role of glucagon-like peptide-1 receptor (GLP-1R) agonists in enhancing endothelial function: a potential avenue for improving heart failure with preserved ejection fraction (HFpEF)
Abstract Heart failure with preserved ejection fraction (HFpEF) is a prevalent and complex condition with limited effective treatments. Endothelial dysfunction is a significant component of HFpEF pathophysiology, and glucagon-like peptide-1 receptor (GLP-1R) agonists have shown potential benefits in...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2025-02-01
|
| Series: | Cardiovascular Diabetology |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s12933-025-02607-w |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1823863290592231424 |
|---|---|
| author | Darshan Hullon Ghasaq K. Subeh Yelizaveta Volkova Karolina Janiec Adam Trach Ruslan Mnevets |
| author_facet | Darshan Hullon Ghasaq K. Subeh Yelizaveta Volkova Karolina Janiec Adam Trach Ruslan Mnevets |
| author_sort | Darshan Hullon |
| collection | DOAJ |
| description | Abstract Heart failure with preserved ejection fraction (HFpEF) is a prevalent and complex condition with limited effective treatments. Endothelial dysfunction is a significant component of HFpEF pathophysiology, and glucagon-like peptide-1 receptor (GLP-1R) agonists have shown potential benefits in improving endothelial function. This study aims to explore the relationship between endothelial dysfunction in HFpEF and the mechanisms of action of GLP-1R agonists, highlighting their potential therapeutic benefits. A comprehensive review of the literature was conducted to examine the etiology of HFpEF, the role of endothelial dysfunction, and the effects of GLP-1R agonists on endothelial function and heart failure outcomes. The findings indicate that HFpEF is associated with various comorbidities, such as obesity, diabetes mellitus, and hypertension, which contribute to endothelial dysfunction. GLP-1R agonists, including semaglutide and liraglutide, have demonstrated significant cardioprotective effects, such as improving vascular endothelial function, reducing inflammation, and preventing atherosclerosis. Clinical trials, such as the STEP-HFpEF trial, have shown positive results in reducing symptoms and physical restrictions in HFpEF patients. GLP-1R agonists present a promising therapeutic option for HFpEF by targeting endothelial dysfunction and other pathophysiological mechanisms. Further research is needed to elucidate the precise mechanisms through which GLP-1R agonists exert their benefits and to establish their long-term safety and efficacy in diverse HFpEF populations. |
| format | Article |
| id | doaj-art-9fd5c6812aed42a99dc7b1e76d8aa3f9 |
| institution | Kabale University |
| issn | 1475-2840 |
| language | English |
| publishDate | 2025-02-01 |
| publisher | BMC |
| record_format | Article |
| series | Cardiovascular Diabetology |
| spelling | doaj-art-9fd5c6812aed42a99dc7b1e76d8aa3f92025-02-09T12:10:57ZengBMCCardiovascular Diabetology1475-28402025-02-0124111510.1186/s12933-025-02607-wThe role of glucagon-like peptide-1 receptor (GLP-1R) agonists in enhancing endothelial function: a potential avenue for improving heart failure with preserved ejection fraction (HFpEF)Darshan Hullon0Ghasaq K. Subeh1Yelizaveta Volkova2Karolina Janiec3Adam Trach4Ruslan Mnevets5MercyOne Clinton Medical CentreUniversity of BaghdadTaras Shevchenko National University of KyivSt. Joseph’s University Medical CenterTaras Shevchenko National University of KyivTaras Shevchenko National University of KyivAbstract Heart failure with preserved ejection fraction (HFpEF) is a prevalent and complex condition with limited effective treatments. Endothelial dysfunction is a significant component of HFpEF pathophysiology, and glucagon-like peptide-1 receptor (GLP-1R) agonists have shown potential benefits in improving endothelial function. This study aims to explore the relationship between endothelial dysfunction in HFpEF and the mechanisms of action of GLP-1R agonists, highlighting their potential therapeutic benefits. A comprehensive review of the literature was conducted to examine the etiology of HFpEF, the role of endothelial dysfunction, and the effects of GLP-1R agonists on endothelial function and heart failure outcomes. The findings indicate that HFpEF is associated with various comorbidities, such as obesity, diabetes mellitus, and hypertension, which contribute to endothelial dysfunction. GLP-1R agonists, including semaglutide and liraglutide, have demonstrated significant cardioprotective effects, such as improving vascular endothelial function, reducing inflammation, and preventing atherosclerosis. Clinical trials, such as the STEP-HFpEF trial, have shown positive results in reducing symptoms and physical restrictions in HFpEF patients. GLP-1R agonists present a promising therapeutic option for HFpEF by targeting endothelial dysfunction and other pathophysiological mechanisms. Further research is needed to elucidate the precise mechanisms through which GLP-1R agonists exert their benefits and to establish their long-term safety and efficacy in diverse HFpEF populations.https://doi.org/10.1186/s12933-025-02607-wHeart failure with preserved ejection fractionEndothelial dysfunctionGLP-1R agonistsSemaglutideLiraglutideCardioprotective effects |
| spellingShingle | Darshan Hullon Ghasaq K. Subeh Yelizaveta Volkova Karolina Janiec Adam Trach Ruslan Mnevets The role of glucagon-like peptide-1 receptor (GLP-1R) agonists in enhancing endothelial function: a potential avenue for improving heart failure with preserved ejection fraction (HFpEF) Cardiovascular Diabetology Heart failure with preserved ejection fraction Endothelial dysfunction GLP-1R agonists Semaglutide Liraglutide Cardioprotective effects |
| title | The role of glucagon-like peptide-1 receptor (GLP-1R) agonists in enhancing endothelial function: a potential avenue for improving heart failure with preserved ejection fraction (HFpEF) |
| title_full | The role of glucagon-like peptide-1 receptor (GLP-1R) agonists in enhancing endothelial function: a potential avenue for improving heart failure with preserved ejection fraction (HFpEF) |
| title_fullStr | The role of glucagon-like peptide-1 receptor (GLP-1R) agonists in enhancing endothelial function: a potential avenue for improving heart failure with preserved ejection fraction (HFpEF) |
| title_full_unstemmed | The role of glucagon-like peptide-1 receptor (GLP-1R) agonists in enhancing endothelial function: a potential avenue for improving heart failure with preserved ejection fraction (HFpEF) |
| title_short | The role of glucagon-like peptide-1 receptor (GLP-1R) agonists in enhancing endothelial function: a potential avenue for improving heart failure with preserved ejection fraction (HFpEF) |
| title_sort | role of glucagon like peptide 1 receptor glp 1r agonists in enhancing endothelial function a potential avenue for improving heart failure with preserved ejection fraction hfpef |
| topic | Heart failure with preserved ejection fraction Endothelial dysfunction GLP-1R agonists Semaglutide Liraglutide Cardioprotective effects |
| url | https://doi.org/10.1186/s12933-025-02607-w |
| work_keys_str_mv | AT darshanhullon theroleofglucagonlikepeptide1receptorglp1ragonistsinenhancingendothelialfunctionapotentialavenueforimprovingheartfailurewithpreservedejectionfractionhfpef AT ghasaqksubeh theroleofglucagonlikepeptide1receptorglp1ragonistsinenhancingendothelialfunctionapotentialavenueforimprovingheartfailurewithpreservedejectionfractionhfpef AT yelizavetavolkova theroleofglucagonlikepeptide1receptorglp1ragonistsinenhancingendothelialfunctionapotentialavenueforimprovingheartfailurewithpreservedejectionfractionhfpef AT karolinajaniec theroleofglucagonlikepeptide1receptorglp1ragonistsinenhancingendothelialfunctionapotentialavenueforimprovingheartfailurewithpreservedejectionfractionhfpef AT adamtrach theroleofglucagonlikepeptide1receptorglp1ragonistsinenhancingendothelialfunctionapotentialavenueforimprovingheartfailurewithpreservedejectionfractionhfpef AT ruslanmnevets theroleofglucagonlikepeptide1receptorglp1ragonistsinenhancingendothelialfunctionapotentialavenueforimprovingheartfailurewithpreservedejectionfractionhfpef AT darshanhullon roleofglucagonlikepeptide1receptorglp1ragonistsinenhancingendothelialfunctionapotentialavenueforimprovingheartfailurewithpreservedejectionfractionhfpef AT ghasaqksubeh roleofglucagonlikepeptide1receptorglp1ragonistsinenhancingendothelialfunctionapotentialavenueforimprovingheartfailurewithpreservedejectionfractionhfpef AT yelizavetavolkova roleofglucagonlikepeptide1receptorglp1ragonistsinenhancingendothelialfunctionapotentialavenueforimprovingheartfailurewithpreservedejectionfractionhfpef AT karolinajaniec roleofglucagonlikepeptide1receptorglp1ragonistsinenhancingendothelialfunctionapotentialavenueforimprovingheartfailurewithpreservedejectionfractionhfpef AT adamtrach roleofglucagonlikepeptide1receptorglp1ragonistsinenhancingendothelialfunctionapotentialavenueforimprovingheartfailurewithpreservedejectionfractionhfpef AT ruslanmnevets roleofglucagonlikepeptide1receptorglp1ragonistsinenhancingendothelialfunctionapotentialavenueforimprovingheartfailurewithpreservedejectionfractionhfpef |